RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
 Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Feb 19, 2013 - 1:22:36 AM
Research Article
Latest Research Channel

subscribe to Latest Research newsletter
Latest Research

   EMAIL   |   PRINT
Switching antiepileptic drugs could increase risk of seizures

Feb 17, 2012 - 5:00:00 AM
White says more randomized controlled trials are needed to clarify why switching medication is a problem for some people. The FDA is currently funding three studies that will further explore the efficacy and safety of brand-name and generic antiepileptic medication. The Epilepsy Foundation of America and the AES are also supporting studies regarding the issue.

 
[RxPG] The substitution of brand-name antiepileptic drugs with cheaper generic equivalents has been an ongoing point of contention among doctors, federal officials and people with epilepsy.

The U.S. Food and Drug Administration claims generic antiepileptic drugs have the same dosage, purity and strength as their brand-name counterparts and the two are interchangeable. But doctors and people with epilepsy remain concerned, citing widespread reports of individuals suffering seizures after switching medication.

A new comprehensive review by pharmacists and doctors at the University of Connecticut and Hartford Hospital shows that it is not the anticonvulsant drugs themselves, but the switching aspect that may be causing the problem.

In a review of 89 different studies dating back to 1950, the researchers found that the efficacy, tolerability and safety of brand-name and generic antiepileptic medications are virtually the same. But switching from one form to the other may cause patients to have more hospitalizations and longer hospital stays. The study results were first reported in a Comparative Effectiveness Review issued by the Agency for Healthcare Research and Quality (AHRQ) in December 2011.

If you have epilepsy and want to start on an antiepileptic drug, the evidence is compelling that it doesn't matter if you use a brand- name or a generic product. But if you're already using one version of drug (generic or brand-name), there may be a concern if you switch to something else, says C. Michael White, a pharmacy professor at the University of Connecticut and director of the federally-designated UConn/Hartford Hospital Evidence-Based Practice Center in Hartford, Conn.

The same concerns apply whether a person switches from a brand-name drug to a generic version or from one generic version to another, White says. While many individuals with epilepsy may not experience any problems switching medications, some people may have complications and the consequences could be severe.

White cautions that the studies showing this increased risk of seizures and complications do not use the strongest study designs and the results are far from definitive. But given the high level of concern regarding different versions of antiepileptic drugs, White says it was important to release these latest findings to inform doctors and patients alike.

It is in cases like this where opinions are the strongest, White says. Should you act on worrisome but weak evidence knowing that costs for patients and insurers will go up and make it logistically more difficult for the pharmacies or do you wait for higher quality studies to come out before taking action? We wanted to share our findings so people can make informed decisions about their care.

Finding the right medication therapy is vitally important for people with epilepsy. A seizure-free epileptic who suffers a sudden breakthrough seizure can be seriously injured in a fall or car accident and experience other life-changing consequences that may affect their ability to do such things as drive a car or hold a job.

A number of states including Hawaii, Illinois, Tennessee and Utah, have passed legislation in recent years preventing the substitution of generic antiepileptic drugs for brand-name products without a patient's consent. Connecticut passed its Patient Prescription Protection Act last year. More than 20 other states have considered passing a law.

Informed consent is the critical issue here, says Alexandra Finucane, executive vice-president of the national Epilepsy Foundation. Many people are able to go from one formulation of an epilepsy drug to another, brand to generic, generic to generic. Some however, are at risk for having a breakthrough seizure when switching among different manufacturers' formulations.

The patient and his or her doctor needs to know and consent in advance when a switch is being considered, as there may be a history of problems with switching and a need for monitoring during the change, Finucane continues. In some cases, the treating doctor will recommend that the patient stays on the same formulation by the same company. For some people with epilepsy, switching could be a matter of life and death.

Generic equivalents of popular antiepileptic drugs such as carbamazepine, phenobarbital, phenytoin and valproic acid have existed for more than a decade. With generic drugs costing anywhere from a few cents to five dollars less per tablet than brand-name medication, they have become a popular option for patients, health insurers, and pharmacies looking to save money.

Unless a patient is specifically prescribed a brand-name medication only, pharmacists can substitute a generic equivalent without informing the patient or their physician. Patients also may have little or no ability to maintain one specific generic medication at the pharmacy they visit as pharmacies frequently change their generic brands based on market supplies, costs and other factors.

The American Academy of Neurology has issued two position papers stating that it has concerns with generic antiepileptic medication and that physicians should approve all generic substitutions. The American Epilepsy Society (AES) and the French Chapter of the International League Against Epilepsy have also expressed concerns while the Italian League Against Epilepsy has concluded that while generic medications offer a valuable, low-cost alternative in epilepsy management, generic substitution is not recommended in patients who have achieved remission using a brand-name product.

White says more randomized controlled trials are needed to clarify why switching medication is a problem for some people. The FDA is currently funding three studies that will further explore the efficacy and safety of brand-name and generic antiepileptic medication. The Epilepsy Foundation of America and the AES are also supporting studies regarding the issue.

The clinical trial data reviewed in the UConn/Hartford Hospital study was limited by the small size of the trials reviewed, the short duration of follow-up study and a lack of clarity as to what specific generic products were used. FDA rules require generic drugs to have the same exact amount of active medication as their brand-name equivalent, and that the rate of absorption (e.g., immediate release, delayed release, extended release) be identical. To be equivalent by FDA standards, the amount of drug absorbed must be statistically similar between a generic product and the brand product.



Related Latest Research News
Drug activates virus against cancer
Bone loss associated with increased production of ROS
Sound preconditioning prevents ototoxic drug-induced hearing loss in mice
Crystal methamphetamine use by street youth increases risk of injecting drugs
Johns Hopkins-led study shows increased life expectancy among family caregivers
Moderate to severe psoriasis linked to chronic kidney disease, say experts
Licensing deal marks coming of age for University of Washington, University of Alabama-Birmingham
Simple blood or urine test to identify blinding disease
Physician job satisfaction driven by quality of patient care
Book explores undiscovered economics of everyday life

Subscribe to Latest Research Newsletter

Enter your email address:


 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)